Methotrexate for Ocular Inflammatory Diseases
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Purpose To evaluate the outcome of treatment with methotrexate for noninfectious ocular inflammation. Design Retrospective cohort study. Participants Patients with noninfectious ocular inflammation managed at 4 tertiary ocular inflammation clinics in the United States observed to add methotrexate as a single, noncorticosteroid immunosuppressive agent to their treatment regimen, between 1979 and 2007, inclusive. Methods Participants were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Demographic and clinical characteristics, including dosage, route of administration of methotrexate, and main outcome measures, were obtained for every eye of every patient at every visit via medical record review by trained expert reviewers. Main Outcome Measures Control of inflammation, corticosteroid-sparing effects, and incidence of and reason for discontinuation of therapy. Results Among 384 patients (639 eyes) observed from the point of addition of methotrexate to an anti-inflammatory regimen, 32.8%, 9.9%, 21.4%, 14.6%, 15.1%, and 6.3%, respectively, had anterior uveitis, intermediate uveitis, posterior or panuveitis, scleritis, ocular mucous membrane pemphigoid, and other forms of ocular inflammation. In these groups, complete suppression of inflammation sustained for ≥28 days was achieved within 6 months in 55.6%, 47.4%, 38.6%, 56.4%, 39.5%, and 76.7%, respectively. Corticosteroid-sparing success (sustained suppression of inflammation with prednisone ≤10 mg/d) was achieved within 6 months among 46.1%, 41.3%, 20.7%, 37.3%, 36.5%, and 50.9%, respectively. Overall, success within 12 months was 66% and 58.4% for sustained control and corticosteroid sparing ≤10 mg), respectively. Methotrexate was discontinued within 1 year by 42% of patients. It was discontinued owing to ineffectiveness in 50 patients (13%); 60 patients (16%) discontinued because of side effects, which typically were reversible with dose reduction or discontinuation. Remission was seen in 43 patients, with 7.7% remitting within 1 year of treatment. Conclusions Our data suggest that adding methotrexate to an anti-inflammatory regimen not involving other noncorticosteroid immunosuppressive drugs is moderately effective for management of inflammatory activity and for achieving corticosteroid-sparing objectives, although many months may be required for therapeutic success. Methotrexate was well tolerated by most patients, and seems to convey little risk of serious side effects during treatment. Financial Disclosure(s) The authors have no proprietary or commercial interests in any of the materials discussed in this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Jabs, D. A., Rosenbaum, J. T., Foster, C. S., Holland, G. N., Jaffe, G. J., Louie, J. S., Nussenblatt, R. B., Stiehm, E. R., Tessler, H., Van Gelder, R. N., et al. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00659-0 · Cited by 995
Self-citationEfficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
Weinblatt, M. E., Coblyn, J. S., Fox, D. A., Fraser, P. A., Holdsworth, D. E., Glass, D. N., & Trentham, D. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121303 · Cited by 872
Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior Uveitis
Nussenblatt, R. B., Palestine, A. G., Chan, C.-C., & Roberge, F. (1985) · Ophthalmology · doi:10.1016/s0161-6420(85)34001-0 · Cited by 684
Self-citationWessels, J. A. M., Huizinga, T. W. J., & Guchelaar, H.-J. (2007) · Rheumatology · doi:10.1093/rheumatology/kem279 · Cited by 337
Methotrexate therapy for chronic noninfectious uveitis
Samson, C. M., Waheed, N., Baltatzis, S., & Foster, C. S. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00576-0 · Cited by 250
Thorne, J. E., Woreta, F., Kedhar, S. R., Dunn, J. P., & Jabs, D. A. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.033 · Cited by 242
Self-citationHoekstra, M., van Ede, A. E., Haagsma, C. J., van de Laar, M. A. F. J., Huizinga, T. W. J., Kruijsen, M. W. M., & Laan, R. F. J. M. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.5.423 · Cited by 224
Hoekstra, M., HAAGSMA, C. J., Neef, C., Proost, J. H., Knuif, A., & van de Laar, M. A. F. J. (2004) · PubMed · Cited by 220
Galor, A., Jabs, D. A., Leder, H. A., Kedhar, S. R., Dunn, J. P., Peters, G. B., & Thorne, J. E. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.04.026 · Cited by 217
Self-citationWalker, A. M., Funch, D., Dreyer, N. A., Tolman, K. G., Kremer, J. M., Alarcón, G. S., Lee, R. G., & Weinblatt, M. E. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360307 · Cited by 206
Low-dose Methotrexate Therapy for Ocular Inflammatory Disease
Shah, S. S., Lowder, C. Y., Schmitt, M. A., Wilke, W. S., Kosmorsky, G. S., & Meisler, D. M. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31790-7 · Cited by 182
Methotrexate treatment for sarcoid-associated panuveitis
Dev, S., McCallum, R. M., & Jaffe, G. J. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90011-8 · Cited by 166
Foeldvari, I., & Wierk, A. (2005) · PubMed · Cited by 156
Kempen, J. H., Gangaputra, S. S., Daniel, E., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., Thorne, J. E., Foster, C. S., Jabs, D. A., et al. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.04.035 · Cited by 136
Self-citationKempen, J. H., Daniel, E., Gangaputra, S. S., Dreger, K. A., Jabs, D. A., Kaçmaz, R. O., Pujari, S. S., Anzaar, F., Foster, C. S., Helzlsouer, K. J., et al. (2008) · Ophthalmic Epidemiology · doi:10.1080/09286580701585892 · Cited by 131
Self-citationHeiligenhaus, A., Mingels, A., Heinz, C., et al. (2007) · European Journal of Ophthalmology · doi:10.1177/112067210701700509 · Cited by 111
Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study.
Lewden, B., Vial, T., Éléfant, É., Nelva, A., Carlier, P., & Descotes, J. (2004) · PubMed · Cited by 94
Tolman, K. G., Clegg, D. O., Lee, R. G., & Ward, J. R. (1985) · PubMed · Cited by 87
Okada, A. A. (2005) · Ocular Immunology and Inflammation · doi:10.1080/09273940590951034 · Cited by 80
The use of low dose methotrexate in children with chronic anterior and intermediate uveitis
Malik, A. R., & Pavesio, C. E. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.054239 · Cited by 76
Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis
Kaplan-Messas, A., Barkana, Y., Avni, I., & Neumann, R. (2003) · Ocular Immunology and Inflammation · doi:10.1076/ocii.11.2.131.15919 · Cited by 72
Dietary myo-inositol therapy in hyperglycemia-induced embryopathy
Khandelwal, M., Reece, E. A., Wu, Y., & Borenstein, M. (1998) · Teratology · doi:10.1002/(sici)1096-9926(199802)57:2<51::aid-tera2>3.0.co;2-9 · Cited by 60
Treatment of Uveitis with Methotrexate
Lazar, M., Weiner, M. J., & Leopold, I. H. (1969) · American Journal of Ophthalmology · doi:10.1016/0002-9394(69)92051-0 · Cited by 56
Use of methotrexate in the management of sight-threatening uveitis
Bom, S., Zamiri, P., & Lightman, S. (2001) · Ocular Immunology and Inflammation · doi:10.1076/ocii.9.1.35.3983 · Cited by 55
Ocular irritation from high-dose methotrexate therapy: Pharmacokinetics of drug in the tear film
Doroshow, J. H., Locker, G. Y., Gaasterland, D., Hubbard, S. P., Young, R. C., & Myers, C. E. (1981) · Cancer · doi:10.1002/1097-0142(19811115)48:10<2158::aid-cncr2820481007>3.0.co;2-i · Cited by 54
Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids.
Holz, F. G., Krastel, H., Breitbart, A., Schwarz-Eywill, M., Pezzutto, A., & Völcker, H. E. (1992) · PubMed · Cited by 48
Baker, K. B., Spurrier, N. J., Watkins, A. S., Smith, J. R., & Rosenbaum, J. T. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.097998 · Cited by 38
Self-citationMethotrexate treatment of uveal disease.
Vg, W. (1966) · PubMed · Cited by 34
Cited by
Varela-Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García-Otero, X., Luzardo-Álvarez, A., Fernández-Ferreiro, A., & Otero-Espinar, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030269 · Cited by 354
EMT and EndMT: Emerging Roles in Age-Related Macular Degeneration
Shu, D. Y., Butcher, E., & Saint-Geniez, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124271 · Cited by 292
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
Dick, A. D., Rosenbaum, J. T., Al-Dhibi, H. A., Belfort, R., Brézin, A. P., Chee, S. P., Davis, J. L., Ramanan, A. V., Sonoda, K.-H., Carreño, E., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.017 · Cited by 285
Self-citationPasadhika, S., & Rosenbaum, J. T. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.08.009 · Cited by 267
Self-citationCyclosporine for Ocular Inflammatory Diseases
Kaçmaz, R. O., Kempen, J. H., Newcomb, C., Daniel, E., Gangaputra, S., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., Thorne, J. E., Jabs, D. A., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.08.010 · Cited by 265
Self-citation
Metadata
- Authors
- Gangaputra, S., Newcomb, C. W., Liesegang, T. L., Kaçmaz, R. O., Jabs, D. A., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., & Thorne, J. E.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 116
- Issue
- 11
- Pages
- 2188-2198.e1
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2116724316
- Cited by
- 330
- References
- 32
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.